- Keryx Biopharmaceuticals announces NDA for hyperphosphatemia treatment in chronic kidney disease patients
- More than a dozen health information exchanges, service providers join Surescripts
- Study: Limiting NPs' scope of practice leads to higher costs
- Senate passes Drug Quality and Security Act
- Walgreens partners with United Nations Foundation's Shot@Life campaign
NEW YORK Drug maker Keryx Biopharmaceuticals has finished enrolling participants for a late-stage clinical trial of a drug for patients on kidney dialysis, Keryx said Tuesday.
The company is conducting a phase-3 trial of Zerenex (ferric citrate) in patients with end-stage kidney disease on dialysis who have excessive phosphorous levels, a condition known as hyperphosphatemia.
Keryx said it expects to complete the study and report top-line data by the end of the year.